Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
McKinsey
Dow
Medtronic
McKesson

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Biapenem

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Biapenem: Patents, clinical trial progress, indications

Biapenem is an investigational drug.

There have been 4 clinical trials for Biapenem. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2017.

The most common disease conditions in clinical trials are Bacterial Infections, Neoplasm Metastasis, and [disabled in preview]. The leading clinical trial sponsors are Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), Haining Health-Coming Biotech Co., Ltd., and [disabled in preview].

There are seven hundred and nineteen US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Biapenem
TitleSponsorPhase
Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid TumorHaining Health-Coming Biotech Co., Ltd.Phase 2
Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in CombinationRempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Phase 1
Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult SubjectsRempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Phase 1

See all Biapenem clinical trials

Clinical Trial Summary for Biapenem

Top disease conditions for Biapenem
Top clinical trial sponsors for Biapenem

See all Biapenem clinical trials

US Patents for Biapenem

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Biapenem   Start Trial Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
Biapenem   Start Trial Cyclic boronic acid ester derivatives and methods of making the same Rempex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Biapenem   Start Trial Methods of treating inflammation associated airway diseases and viral infections WASHINGTON STATE UNIVERSITY (Pullman, WA) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)   Start Trial
Biapenem   Start Trial Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same PharmaIN Corporation (Bothell, WA)   Start Trial
Biapenem   Start Trial Inhibitors of metallo-.beta.-lactamase-enzymes McMaster University (Hamilton, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Biapenem

Drugname Country Document Number Estimated Expiration Related US Patent
Biapenem Australia 2011210567 2030-01-29   Start Trial
Biapenem Canada 2787784 2030-01-29   Start Trial
Biapenem European Patent Office 2528893 2030-01-29   Start Trial
Biapenem European Patent Office 3138838 2030-01-29   Start Trial
Biapenem Japan 2013518816 2030-01-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Boehringer Ingelheim
Express Scripts
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.